Syndax Pharmaceuticals (SNDX) Scheduled to Post Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to announce its earnings results after the market closes on Tuesday, November 5th. Analysts expect Syndax Pharmaceuticals to post earnings of ($1.13) per share for the quarter.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.11. The company had revenue of $3.50 million for the quarter. During the same quarter in the prior year, the company posted ($0.64) earnings per share. The firm’s revenue for the quarter was up 3499999990.0% compared to the same quarter last year. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syndax Pharmaceuticals Stock Down 0.9 %

Shares of NASDAQ SNDX traded down $0.17 during trading on Wednesday, hitting $18.91. 10,485 shares of the company traded hands, compared to its average volume of 1,048,714. The firm has a market capitalization of $1.61 billion, a P/E ratio of -5.87 and a beta of 0.91. The company has a 50-day moving average price of $19.20 and a 200-day moving average price of $20.38. Syndax Pharmaceuticals has a 1 year low of $12.95 and a 1 year high of $25.34.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SNDX shares. Citigroup upped their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. HC Wainwright increased their target price on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Bank of America raised their price target on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 15th. UBS Group began coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, October 24th. They set a “buy” rating and a $37.00 price objective for the company. Finally, Barclays raised their target price on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.90.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).